U.S. Capital Wealth Advisors, LLC
Position in VKTX — Viking Therapeutics, Inc.
CIK 1808915
AUSTIN, TX
Position in VKTX
as of Mar 31, 2026
· filed Apr 7, 2026
Position Value
$2,173,021
-$255,454 QoQ
Shares Held
66,780
-3.3% QoQ
Ownership
0.057%
of shares outstanding
% of Portfolio
0.08%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in VKTX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026U.S. Capital Wealth Advisors, LLC holds $11,669,198 across 6 Biotechnology names. VKTX ranks #2 (18.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
24,537 | $8,118,557 | |
| 2 | VKTX |
Viking Therapeutics, Inc.
This page
|
66,780 | $2,173,021 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,432 | $1,106,420 | |
| 4 | SMMT |
Summit Therapeutics Inc.
|
12,009 | $227,690 | |
| 5 | ALDX |
Aldeyra Therapeutics, Inc.
|
15,805 | $26,710 | |
| 6 | IKT |
Inhibikase Therapeutics, Inc.
|
10,000 | $16,800 |
All Filings in VKTX
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,173,021 | 66,780 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | $2,428,475 | 69,030 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $2,474,656 | 94,165 | Shares | Sole | 2025-10-09 | |
| 2025-06-30 | $1,683,969 | 63,546 | Shares | Sole | 2025-07-14 | |
| 2025-03-31 | $863,386 | 35,751 | Shares | Sole | 2025-04-29 | |
| 2024-12-31 | $1,777,561 | 44,174 | Shares | Sole | 2025-01-24 | |
| 2024-09-30 | $1,458,978 | 23,045 | Shares | Sole | 2024-10-22 | |
| 2024-06-30 | $382,997 | 7,225 | Shares | Sole | 2024-07-11 | |
| No filing history on record for this holder in this stock. | ||||||